ZBAO

ZBAO
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $20.391M ▲ | $2.655M ▼ | $-211.151K ▼ | -1.036% ▼ | $-0.007 ▼ | $729.738K ▲ |
| Q1-2025 | $10.429M ▼ | $2.761M ▲ | $-45.927K ▼ | -0.44% ▼ | $-0.002 ▼ | $274.28K ▼ |
| Q4-2024 | $13.778M ▲ | $1.803M ▼ | $3.021M ▲ | 21.926% ▼ | $0.096 ▲ | $2.933M ▲ |
| Q3-2024 | $6.884M ▼ | $1.815M ▼ | $1.509M ▲ | 21.926% ▲ | $0.049 ▲ | $1.295M ▲ |
| Q2-2024 | $11.641M | $2.699M | $-1.181M | -10.143% | $-0.038 | $-1.077M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $18.346M ▲ | $43.152M ▼ | $33.072M ▼ | $10.08M ▼ |
| Q1-2025 | $4.006M ▲ | $44.884M ▼ | $34.514M ▼ | $10.37M ▼ |
| Q4-2024 | $2.401M ▲ | $208.788M ▲ | $144.797M ▲ | $63.991M ▲ |
| Q3-2024 | $554.304K ▼ | $28.916M ▼ | $20.054M ▼ | $8.862M ▼ |
| Q2-2024 | $6.881M | $234.184M | $218.824M | $15.359M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-211.151K ▼ | $10.336M ▲ | $-609.47K ▼ | $3.208M ▲ | $12.684M ▲ | $0 ▼ |
| Q1-2025 | $-45.927K ▼ | $5.287M ▲ | $-311.716K ▼ | $1.641M ▼ | $0 ▲ | $5.287M ▲ |
| Q4-2024 | $3.021M ▲ | $-12.356M ▼ | $-45.531K ▼ | $3.002M ▲ | $-9.775M ▼ | $-12.394M ▼ |
| Q3-2024 | $1.509M ▲ | $-6.192M ▼ | $-22.694K ▲ | $1.498M ▲ | $0 ▼ | $-6.211M ▼ |
| Q2-2024 | $-602.017K | $11.828M | $-36.558K | $1.281M | $13.391M | $5.994M |
Five-Year Company Overview
Income Statement

Balance Sheet

Cash Flow

Competitive Edge

Innovation and R&D

Summary
Overall, Zhibao looks like an early‑stage, high‑growth insurtech platform with a distinctive embedded distribution model and a strong emphasis on technology and partnerships. Financially, it has moved from loss‑making to modest profitability and has strengthened its balance sheet, but its absolute scale is still very small and the lack of clear cash‑flow disclosure limits visibility into underlying health. Strategically, its first‑mover advantage in 2B2C embedded insurance, broad partner network, and AI‑driven platform offer meaningful upside potential, but they come with notable execution, regulatory, and competitive risks. The recent filing delay and Nasdaq deficiency letter underscore that this is a developing story, where governance, transparency, and sustained profitable growth will be key factors to monitor over the coming years.
NEWS
November 21, 2025 · 9:00 PM UTC
Zhibao Technology Announces Receipt of Nasdaq Deficiency Letter
Read more
November 18, 2025 · 5:30 AM UTC
Zhibao Technology Issues Update on Delay in Filing 20-F Annual Report
Read more
November 14, 2025 · 9:00 AM UTC
Zhibao's Subsidiary Receives 'Good' Financial Strength and Long-Term Issuer Credit Ratings from AM Best
Read more
November 3, 2025 · 8:00 AM UTC
Zhibao Technology Inc. Announces Postponement of FY2025 Financial Results and Earnings Conference Call
Read more
October 23, 2025 · 8:00 AM UTC
Zhibao Technology Announces Fiscal Year 2025 Earnings Call and Issues 60-80% Revenue Growth Guidance
Read more
About Zhibao Technology Inc. Class A Ordinary Shares
https://www.zhibao-tech.comZhibao Technology Inc., through its subsidiaries, provides digital insurance brokerage services in China. It also offers managing general underwriter services; healthcare; and offline insurance brokerage consulting services. The company was founded in 2015 and is based in Shanghai, China.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $20.391M ▲ | $2.655M ▼ | $-211.151K ▼ | -1.036% ▼ | $-0.007 ▼ | $729.738K ▲ |
| Q1-2025 | $10.429M ▼ | $2.761M ▲ | $-45.927K ▼ | -0.44% ▼ | $-0.002 ▼ | $274.28K ▼ |
| Q4-2024 | $13.778M ▲ | $1.803M ▼ | $3.021M ▲ | 21.926% ▼ | $0.096 ▲ | $2.933M ▲ |
| Q3-2024 | $6.884M ▼ | $1.815M ▼ | $1.509M ▲ | 21.926% ▲ | $0.049 ▲ | $1.295M ▲ |
| Q2-2024 | $11.641M | $2.699M | $-1.181M | -10.143% | $-0.038 | $-1.077M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $18.346M ▲ | $43.152M ▼ | $33.072M ▼ | $10.08M ▼ |
| Q1-2025 | $4.006M ▲ | $44.884M ▼ | $34.514M ▼ | $10.37M ▼ |
| Q4-2024 | $2.401M ▲ | $208.788M ▲ | $144.797M ▲ | $63.991M ▲ |
| Q3-2024 | $554.304K ▼ | $28.916M ▼ | $20.054M ▼ | $8.862M ▼ |
| Q2-2024 | $6.881M | $234.184M | $218.824M | $15.359M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-211.151K ▼ | $10.336M ▲ | $-609.47K ▼ | $3.208M ▲ | $12.684M ▲ | $0 ▼ |
| Q1-2025 | $-45.927K ▼ | $5.287M ▲ | $-311.716K ▼ | $1.641M ▼ | $0 ▲ | $5.287M ▲ |
| Q4-2024 | $3.021M ▲ | $-12.356M ▼ | $-45.531K ▼ | $3.002M ▲ | $-9.775M ▼ | $-12.394M ▼ |
| Q3-2024 | $1.509M ▲ | $-6.192M ▼ | $-22.694K ▲ | $1.498M ▲ | $0 ▼ | $-6.211M ▼ |
| Q2-2024 | $-602.017K | $11.828M | $-36.558K | $1.281M | $13.391M | $5.994M |
Five-Year Company Overview
Income Statement

Balance Sheet

Cash Flow

Competitive Edge

Innovation and R&D

Summary
Overall, Zhibao looks like an early‑stage, high‑growth insurtech platform with a distinctive embedded distribution model and a strong emphasis on technology and partnerships. Financially, it has moved from loss‑making to modest profitability and has strengthened its balance sheet, but its absolute scale is still very small and the lack of clear cash‑flow disclosure limits visibility into underlying health. Strategically, its first‑mover advantage in 2B2C embedded insurance, broad partner network, and AI‑driven platform offer meaningful upside potential, but they come with notable execution, regulatory, and competitive risks. The recent filing delay and Nasdaq deficiency letter underscore that this is a developing story, where governance, transparency, and sustained profitable growth will be key factors to monitor over the coming years.
NEWS
November 21, 2025 · 9:00 PM UTC
Zhibao Technology Announces Receipt of Nasdaq Deficiency Letter
Read more
November 18, 2025 · 5:30 AM UTC
Zhibao Technology Issues Update on Delay in Filing 20-F Annual Report
Read more
November 14, 2025 · 9:00 AM UTC
Zhibao's Subsidiary Receives 'Good' Financial Strength and Long-Term Issuer Credit Ratings from AM Best
Read more
November 3, 2025 · 8:00 AM UTC
Zhibao Technology Inc. Announces Postponement of FY2025 Financial Results and Earnings Conference Call
Read more
October 23, 2025 · 8:00 AM UTC
Zhibao Technology Announces Fiscal Year 2025 Earnings Call and Issues 60-80% Revenue Growth Guidance
Read more

CEO
Botao Ma
Compensation Summary
(Year 2024)

CEO
Botao Ma
Compensation Summary
(Year 2024)
Ratings Snapshot
Rating : B

